Related references
Note: Only part of the references are listed.Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Xiulong Shen et al.
NUCLEIC ACIDS RESEARCH (2018)
Adenosine-to-Inosine RNA Editing in Health and Disease
Aikaterini Gatsiou et al.
ANTIOXIDANTS & REDOX SIGNALING (2018)
Aptamers as targeted therapeutics: current potential and challenges
Jiehua Zhou et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
C-C motif-ligand 2 inhibition with emapticap pegol ( NOX-E36) in type 2 diabetic patients with albuminuria
Jan Menne et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2017)
CRISPR/Cas9 with single guide RNA expression driven by small tRNA promoters showed reduced editing efficiency compared to a U6 promoter
Yuda Wei et al.
RNA (2017)
Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium
Christoph Waldeyer et al.
EUROPEAN HEART JOURNAL (2017)
Antisense oligonucleotide therapy for spinocerebellar ataxia type 2
Daniel R. Scoles et al.
NATURE (2017)
Cellular uptake and trafficking of antisense oligonucleotides
Stanley T. Crooke et al.
NATURE BIOTECHNOLOGY (2017)
Overcoming cellular barriers for RNA therapeutics
Steven F. Dowdy
NATURE BIOTECHNOLOGY (2017)
Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing
Hao Yin et al.
NATURE BIOTECHNOLOGY (2017)
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rajesha Rupaimoole et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Mark J. Graham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Kevin Fitzgerald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Site-directed RNA repair of endogenous Mecp2 RNA in neurons
John R. Sinnamon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
RNA editing with CRISPR-Cas13
David B. T. Cox et al.
SCIENCE (2017)
Advances in the delivery of RNA therapeutics: from concept to clinical reality
James C. Kaczmarek et al.
GENOME MEDICINE (2017)
Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials
Aris Karatasakis et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab
Nihar R. Desai et al.
JAMA CARDIOLOGY (2017)
Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy
Merrill D. Benson et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2017)
Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers
Thomas Schluep et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Heart Disease and Stroke Statistics-2017 Update A Report From the American Heart Association
Emelia J. Benjamin et al.
CIRCULATION (2017)
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Alexis C. Komor et al.
CELL (2017)
Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy
Chengzu Long et al.
SCIENCE (2016)
Opportunities for the Cardiovascular Community in the Precision Medicine Initiative
Svati H. Shah et al.
CIRCULATION (2016)
The American Heart Association’s New Institute for Precision Cardiovascular Medicine
Steven R. Houser
CIRCULATION (2016)
The Future of Cardiovascular Therapeutics
Calum A. MacRae et al.
CIRCULATION (2016)
Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
Andres Digenio et al.
DIABETES CARE (2016)
Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer
Nancy J. Ganson et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia
P. Barton Duell et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2016)
Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results
Xiaohong Yang et al.
JOURNAL OF LIPID RESEARCH (2016)
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Nicholas J. Viney et al.
LANCET (2016)
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial
A. Michael Lincoff et al.
LANCET (2016)
Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity
Josh Tycko et al.
MOLECULAR CELL (2016)
A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice
Yang Yang et al.
NATURE BIOTECHNOLOGY (2016)
Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo
Hao Yin et al.
NATURE BIOTECHNOLOGY (2016)
Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation
Konstantinos Stellos et al.
NATURE MEDICINE (2016)
Ten years of anti-vascular endothelial growth factor therapy
Napoleone Ferrara et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Frederick F. Dewey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Splice-switching antisense oligonucleotides as therapeutic drugs
Mallory A. Havens et al.
NUCLEIC ACIDS RESEARCH (2016)
C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector
Omar O. Abudayyeh et al.
SCIENCE (2016)
STRUCTURE A Big Bang in spliceosome structural biology
Jamie H. D. Cate
SCIENCE (2016)
Apolipoprotein C3 gene variants and the risk of coronary heart disease: A meta-analysis
Yan Li et al.
META GENE (2016)
Preclinical and clinical development of siRNA-based therapeutics
Gulnihal Ozcan et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial
Eveline P. van Poelgeest et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
The effect of C-reactive protein reduction with a highly specific antisense oligonucleotide on atrial fibrillation assessed using beat-to-beat pacemaker Holter follow-up
Conn Sugihara et al.
JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY (2015)
Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
Romain Capoulade et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
Sotirios Tsimikas et al.
LANCET (2015)
Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis
Einav Shoshan et al.
NATURE CELL BIOLOGY (2015)
Knocking down disease: a progress report on siRNA therapeutics
Anders Wittrup et al.
NATURE REVIEWS GENETICS (2015)
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Daniel Gaudet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study
Ole B. Suhr et al.
ORPHANET JOURNAL OF RARE DISEASES (2015)
Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis
Marshelle S. Warren et al.
ARTHRITIS RESEARCH & THERAPY (2015)
siRNA Versus miRNA as Therapeutics for Gene Silencing
Jenny K. W. Lam et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
Raul D. Santos et al.
EUROPEAN HEART JOURNAL (2015)
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Kevin Fitzgerald et al.
LANCET (2014)
Therapeutic targeting of microRNAs: current status and future challenges
Zhonghan Li et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
Jacy Crosby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study
Thomas J. Povsic et al.
EUROINTERVENTION (2014)
Effects of an Antisense Oligonucleotide Inhibitor of C-Reactive Protein Synthesis on the Endotoxin Challenge Response in Healthy Human Male Volunteers
Robert Noveck et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2014)
Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic
Pedro M. D. Moreno et al.
FRONTIERS IN CHEMISTRY (2014)
Eteplirsen for the Treatment of Duchenne Muscular Dystrophy
Jerry R. Mendell et al.
ANNALS OF NEUROLOGY (2013)
Angptl3 Deficiency Is Associated With Increased Insulin Sensitivity, Lipoprotein Lipase Activity, and Decreased Serum Free Fatty Acids
Marius R. Robciuc et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B
Stanley T. Crooke et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Apolipoprotein C-III Going Back to the Future for a Lipid Drug Target
Murray W. Huff et al.
CIRCULATION RESEARCH (2013)
Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans
Mark J. Graham et al.
CIRCULATION RESEARCH (2013)
Influence of Apolipoproteins on the Association Between Lipids and Insulin Sensitivity A cross-sectional analysis of the RISC Study
Simona Baldi et al.
DIABETES CARE (2013)
Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons
Takenari Yamashita et al.
EMBO MOLECULAR MEDICINE (2013)
MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma
Philipp Wiesner et al.
JOURNAL OF LIPID RESEARCH (2013)
Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk
Gregory S. Thomas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma
Lei Lei Chen et al.
NATURE MEDICINE (2013)
Argonaute proteins: functional insights and emerging roles
Gunter Meister
NATURE REVIEWS GENETICS (2013)
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
Teresa Coelho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Treatment of HCV Infection by Targeting MicroRNA
Harry L. A. Janssen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
RNA-Guided Human Genome Engineering via Cas9
Prashant Mali et al.
SCIENCE (2013)
Multiplex Genome Engineering Using CRISPR/Cas Systems
Le Cong et al.
SCIENCE (2013)
Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia
Evan A. Stein et al.
CIRCULATION (2012)
High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial
Jessica M. Pena et al.
EUROPEAN HEART JOURNAL (2012)
Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
Maartje E. Visser et al.
EUROPEAN HEART JOURNAL (2012)
Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells
Yukti Choudhury et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Safety and Efficacy of Mipomersen Administered as Add-on Therapy in Patients with Hypercholesterolemia and High Cardiovascular Risk†
William C. Cromwell et al.
Journal of Clinical Lipidology (2012)
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Ryszard Kole et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy
Mary P. McGowan et al.
PLOS ONE (2012)
Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function
Bianca C. Bernardo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity
Martin Jinek et al.
SCIENCE (2012)
Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis
Katey J. Rayner et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Silencing of microRNA families by seed-targeting tiny LNAs
Susanna Obad et al.
NATURE GENETICS (2011)
The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli
Rimantas Sapranauskas et al.
NUCLEIC ACIDS RESEARCH (2011)
High-Sensitivity C-Reactive Protein as a Predictor of Atrial Fibrillation Recurrence after Primary Circumferential Pulmonary Vein Isolation
Jun Liu et al.
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY (2011)
Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration
Shaker A. Mousa et al.
BIODRUGS (2010)
First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention
Mauricio G. Cohen et al.
CIRCULATION (2010)
Lipoprotein(a) as a cardiovascular risk factor: current status
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2010)
Intracardiac and extracardiac markers of inflammation during atrial fibrillation
Gregory M. Marcus et al.
HEART RHYTHM (2010)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2010)
Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application
Aimee L. Jackson et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
On the road to reading the RNA-interference code
Haruhiko Siomi et al.
NATURE (2009)
Long non-coding RNAs: insights into functions
Tim R. Mercer et al.
NATURE REVIEWS GENETICS (2009)
Lipoprotein(a) levels and risk of future coronary heart disease
Anna Bennet et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
First-in-human evaluation of anti-von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers
James C. Gilbert et al.
CIRCULATION (2007)
RNA maps reveal new RNA classes and a possible function for pervasive transcription
Philipp Kapranov et al.
SCIENCE (2007)
Antisense oligonucleotides: From design to therapeutic application
JHP Chan et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2006)
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
EWM Ng et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation
TA Rand et al.
CELL (2005)
Argonaute2 is the catalytic engine of mammalian RNAi
JD Liu et al.
SCIENCE (2004)
Pegaptanib for neovascular age-related macular degeneration
ES Gragoudas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation
J Dernellis et al.
EUROPEAN HEART JOURNAL (2004)
Activation of the interferon system by short-interfering RNAs
CA Sledz et al.
NATURE CELL BIOLOGY (2003)
RNA aptamers as reversible antagonists of coagulation factor IXa
CP Rusconi et al.
NATURE (2002)
Lipoprotein(a) and coronary heart disease - Meta-analysis of prospective studies
J Danesh et al.
CIRCULATION (2000)
Potent and nontoxic antisense oligonucleotides containing locked nucleic acids
C Wahlestedt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly
TE Strandberg et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
Share Paper
